NEW YORK, Sept. 19, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com)has been investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company").
On September 18, 2018, Reuters reported that California Insurance Commissioner Dave
The case filed in Alameda County Superior Court, California alleges that private insurers have paid out $1.2 billion in Humira-related pharmacy claims. The allegations of AbbVie's alleged misconduct were brought to the attention of the department by a whistleblower, a registered nurse who was employed as an AbbVie Nurse Ambassador in Florida.
On September 18, 2018, AbbVie shares declined from a closing price on September 17, 2018 of $95.37 per share, to close at $92.61 per share, a decline of $2.76 per share, or approximately 3%, on heavier than usual volume.
If you are an investor in AbbVie and would like to discuss our investigation, please contact us by emailing firstname.lastname@example.org or by calling 800-290-1952.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this Notice, the action, your rights, or your interests, please contact:
Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP850 Third Avenue, 14th FloorNew York, New York 10022(800) 290-1952(212) 687-1980Fax: (212) 687-7714E-mail: email@example.com
Laurence D. KingKAPLAN FOX & KILSHEIMER LLP350 Sansome Street, Suite 400 San Francisco, California 94104(415) 772-4700Fax: (415) 772-4707E-mail: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-investigates-abbvie-inc-300715382.html
SOURCE Kaplan Fox & Kilsheimer LLP
Subscribe to our Free Newsletters!